Biotech & Genomic Medicine▲
Five Biotech Stocks Deliver Big Gains With Key Catalysts Ahead
Five biotech stocks featured on RTTNews have delivered substantial gains, with upcoming catalysts that could drive further upside. uniQure N.V. surged 186% since August 2025, driven by positive data for its Huntington's disease gene therapy AMT-130, and is on track to submit regulatory filings in the third quarter of 2026. CareDx Inc. gained 138% since June 2025 after a series of strong earnings reports, raised guidance, and the acquisition of Naveris, with the commercial launch of the NavDx liquid biopsy test as a key catalyst. Adaptive Biotechnologies Corp. rose 130% since May 2025, supported by growing adoption of its clonoSEQ MRD test and multiple guidance raises, with the planned separation of its Immune Medicine business as a potential catalyst. Enliven Therapeutics Inc. jumped 207% since November 2025 on positive Phase 1 data for its chronic myeloid leukemia drug ELVN-001, and expects to initiate a Phase 3 trial in the second half of 2026. Amylyx Pharmaceuticals Inc. climbed 217% since June 2025, with a pivotal Phase 3 data readout for its post-bariatric hypoglycemia drug Avexitide anticipated in the third quarter of 2026.
RTTNews·25dRead more ▾
Biotech & Genomic Medicine▲
Biotech Stocks CareDx, Integra, Agilon, Bioventus, Enliven Hit 52-Week Highs
Several biotech stocks reached 52-week highs on July 16, 2026, driven by upcoming quarterly reports and conference participation. CareDx saw its stock hit a 52-week high of 40.38%, rising over 25% intraday, after announcing Medicare coverage for its AlloSure, AlloMap, and AlloSeq transplant rejection tests and reporting a 39% first-quarter revenue increase to $118 million. Integra LifeSciences shares rose over 5% to a 52-week high of $20.26, supported by recent product approvals and first-quarter revenue of $391.9 million. Agilon Health, which serves over 536,000 senior members through its subscription platform, expects full-year 2026 revenue of $5.68 billion. Bioventus touched a 52-week high of $12.53, rising over 3%, with first-quarter revenue up 7% to $132 million. Enliven Therapeutics shares rose over 6% to a 52-week high of $53.89 following encouraging interim data for its leukemia drug candidate and a recent public offering that raised about $460 million.
RTTNews·41dRead more ▾
ELVN
Enliven Therapeutics Director Lori Anne Kunkel Sells $345,000 in Stock Under Prearranged Plan
Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000 on June 5, 2026, according to an SEC filing. The sale, executed under a Rule 10b5-1 trading plan adopted in March 2026, reduced her direct holdings by 16% to 51,884 shares. At the time of the transaction, Enliven shares had returned 62.4% over the prior year, and the stock has since surged to a 130% gain over the past 12 months. The clinical-stage biotech is preparing to launch a Phase 3 trial for its chronic myeloid leukemia candidate ELVN-001 later this year and recently strengthened its balance sheet with an upsized public offering that generated roughly $460 million in gross proceeds.
The Motley Fool·60dRead more ▾
OrbiMed Sells $39 Million of Enliven Therapeutics Stock After 130% Rally
OrbiMed Advisors, a 10% owner of Enliven Therapeutics, disclosed the indirect sale of 860,123 shares for approximately $39.0 million. The shares were sold at around $45.36 each, while the stock closed at $45.96 on June 22, 2026, and subsequently rose to $50 by June 26. Following the transaction, OrbiMed still holds 6,555,102 shares indirectly, representing a reduction of 11.60% of its prior indirect holdings. Enliven, a clinical-stage biotech focused on kinase inhibitors, has seen its stock gain 130% over the past year and recently announced positive Phase 1 data for its lead candidate ELVN-001, with plans to launch a pivotal Phase 3 trial in the second half of 2026.
The Motley Fool·60dRead more ▾
ELVN▼
Orbimed Advisors Sells 281,408 Shares of Enliven Therapeutics for $12.67 Million
Medical and biotech-focused hedge fund Orbimed Advisors reported the sale of 281,408 shares of Enliven Therapeutics for approximately $12.67 million, according to an SEC Form 4 filing. The sale accounted for 3.67% of the reporting entity's indirect common stock holdings, leaving it with 7,388,902 shares and a continued material investment in the clinical-stage biotech. All shares were held indirectly through entities such as OrbiMed Genesis Master Fund and OrbiMed Private Investments VII. This is the second reported open-market sale in two years, following a prior disposition of 1,033,300 shares. The transaction comes after Enliven announced positive Phase III data for a leukemia drug, and Orbimed has since filed Form 144 paperwork to sell additional shares.
The Motley Fool·63dRead more ▾